Arcturus Therapeutics Holdings Inc. Stock News

An EUA for ARCT-154 as a COVID-19 vaccine in Vietnam has been submitted, with expected approval in 2022. A phase 2 study using ARCT-810 as a treatment option for patients with OTC deficiency is expect

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2022 Results Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Deepankar Roy - Senior Director, Investor Relations Joseph Payne

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -50.39% and 60.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months a

Phase 3 pivotal study succeeds in endpoints using ARCT-154 for Covid-19; Emergency Use Authorization submitted to Vietnam with possible approval for use in coming weeks/months. Ability to expand ARCT-

Shares of Acturus Therapeutics Holdings Inc. ARCT, -1.43% were down 2.3% in trading on Wednesday after the company said two doses of its experimental COVID-19 vaccine had an efficacy rate of 55% again

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s traded shares stood at 0.49 million during the last session, with the company’s beta value hitting 2.75. At the close of trading, the stock’s price was $18.85, to imply a decrease of -7.37% or -$1.5 in intraday trading. The ARCT share’s 52-week high remains $65.00, putting it -244.83% down since … Following A -20.26% Weekly Decline, Is It Still A Buy For Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT)? Read More »

It''s not likely, but it could still end up being a good investment.

It's not likely, but it could still end up being a good investment.

Arcturus Therapeutics press release (ARCT): Q4 GAAP EPS of -$1.47 beats by $0.16.Revenue of $5.8M (+163.6% Y/Y) misses by $5.85M.

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress

Arcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q4 2021 Results - Earnings Call Transcript

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 16.95% and 55.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc